Brief: Nanoviricides Obtained Right Of First Refusal For All Antiviral Drug Developments
26/09/2024 11:34
Sept 26 (Reuters) - NanoViricides Inc NNVC.A :
* NANOVIRICIDES: OBTAINED RIGHT OF FIRST REFUSAL FOR ALL
ANTIVIRAL
DRUG DEVELOPMENTS FROM RESEARCH AND DEVELOPMENT FIRM THERACOUR
PHARMA
Further company coverage: NNVC.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NanoViricides,
See all newsExplainer: What do we know about the Bundibugyo strain of the Ebola virus?
Brief: anoViricides Signs Agreement for Orphan Drug Strategy of NV-387 for Mpox, Smallpox, and Measles
Brief: Nanoviricides Says NV-387 Shows Activity Against Measles Virus In Humanized Animal Model
Brief: Nanoviricides Co's Business Not Affected By Tariff Policies Of Us Government Or Corresponding Retaliatory Policies Of Other Governments
Brief: Nanoviricides Obtained Right Of First Refusal For All Antiviral Drug Developments